Abstract
Accumulating evidence indicates that regulatory T cells (Treg) are a distinct group of immune cells that are essential in maintaining immunologic homeostasis, largely by their ability to suppress responses mediated by other populations of immune cells. In a microbial infection, this suppressive function can be temporally overridden via different mechanisms so that the immune system can mount efficient antimicrobial immunity. However, if Tregs suppressive function is not restored after the elimination of pathogens, the resulting immune hyperactivity would injure self tissues and autoimmune diseases may occur. In case of cancer, the overexpressed self-antigens can induce tumor/self-specific Treg cells that suppress effective antitumor responses. A wealth of evidence clearly shows that some microbes and their products, such as CpG-ODN, OK-432 and BCG, are effective in cancer treatment, most likely by suppression of Tregs function. Therefore, the search for approaches which can override Tregs suppressive functions and trigger an efficient antitumor immunity is crucial to the development of effective cancer immunotherapy.
Current Cancer Therapy Reviews
Title: Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Volume: 6 Issue: 1
Author(s): Xinhai Zhang, Rick F. Thorne, Thomas E. Wagner and Yanzhang Wei
Affiliation:
Abstract: Accumulating evidence indicates that regulatory T cells (Treg) are a distinct group of immune cells that are essential in maintaining immunologic homeostasis, largely by their ability to suppress responses mediated by other populations of immune cells. In a microbial infection, this suppressive function can be temporally overridden via different mechanisms so that the immune system can mount efficient antimicrobial immunity. However, if Tregs suppressive function is not restored after the elimination of pathogens, the resulting immune hyperactivity would injure self tissues and autoimmune diseases may occur. In case of cancer, the overexpressed self-antigens can induce tumor/self-specific Treg cells that suppress effective antitumor responses. A wealth of evidence clearly shows that some microbes and their products, such as CpG-ODN, OK-432 and BCG, are effective in cancer treatment, most likely by suppression of Tregs function. Therefore, the search for approaches which can override Tregs suppressive functions and trigger an efficient antitumor immunity is crucial to the development of effective cancer immunotherapy.
Export Options
About this article
Cite this article as:
Zhang Xinhai, Thorne F. Rick, Wagner E. Thomas and Wei Yanzhang, Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope, Current Cancer Therapy Reviews 2010; 6(1) . https://dx.doi.org/10.2174/157339410790596470
DOI https://dx.doi.org/10.2174/157339410790596470 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Editorial [Hot Topic: Innate Immunity and Autoimmune Disease (Guest Editors: F. Susan Wong and Li Wen)]
Current Molecular Medicine NKT Cell-Stimulating Synthetic Glycolipids as Potential Therapeutics for Autoimmune Disease
Current Topics in Medicinal Chemistry Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Cytokines and their Antagonists as Therapeutic Agents
Current Medicinal Chemistry Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Neuropeptide Receptors in Intestinal Disease: Physiology and Therapeutic Potential
Current Pharmaceutical Design Recent Developments in the Discovery of Selective Glucocorticoid Receptor Modulators (SGRMs)
Current Topics in Medicinal Chemistry Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine Autoimmunity and Apoptosis - Therapeutic Implications
Current Medicinal Chemistry The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Current Pharmaceutical Design Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis
Current Pharmaceutical Design Some Recent Insights into the Prothrombogenic Mechanisms of Antiphospholipid Antibodies
Current Medicinal Chemistry Basement Membrane Peptides: Functional Considerations and Biomedical Applications in Autoimmunity
Current Medicinal Chemistry Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HSP60 as a Drug Target
Current Pharmaceutical Design Hot topic: Editorial [Therapeutic Potential of Peptide Motifs - Part IV] (Jean Claude Herve)
Current Pharmaceutical Design Directing an Appropriate Immune Response: The Role of Defense Collagens and other Soluble Pattern Recognition Molecules
Current Drug Targets Somatic Genome Variations in Health and Disease
Current Genomics